Pharma BD Deal Intelligence
Bayer's $2.9B acquisition of Algeta secured full ownership of Xofigo, a radiotherapeutic for cancer, giving Bayer sole control over the drug's global commercialization.
Bayer acquired Algeta for ~$2.9B for radiotherapeutic Xofigo for cancer.
The targeted alpha therapy (TAT) category has exploded in 2023-2025 as beta-emitter Pluvicto's success validated the architecture. Thorium-227 targeted alpha conjugates (direct MOA): Bayer's internal TTC platform (PSMA-TTC/BAY 3546828 Phase 1 mCRPC, mesothelin-TTC/BAY 2287411 Phase 1) is the lead program; no other major thorium-227 conjugate at late stage. Actinium-225 targeted alpha conjugates (competing alpha MOA): Novartis's 225Ac-PSMA-617 (actinium analog of Pluvicto, Phase 1/2), Fusion/AstraZeneca's FPI-2059 (NTSR1) and FPI-2068 (EGFR/cMET, Phase 1, $2B 2024 AstraZeneca acquisition), RayzeBio/BMS's RYZ101 (225Ac-DOTATATE, Phase 3 ACTION-1 GEP-NET, $4.1B 2023 BMS acquisition), and Lantheus's PNT2002 (177Lu-partner, acquired). Lead-212 and Astatine-211 alpha platforms: Perspective Therapeutics' VMT-alpha-NET (212Pb-DOTAMTATE, Phase 1/2 NET) and Orano Med's AlphaMedix. Beta-emitter radioligand (category benchmark): Novartis's Pluvicto (177Lu-PSMA-617, approximately $1.4B 2024 sales) and Lutathera (177Lu-DOTATATE, approximately $720M 2024). Alpha-emitting radium: Bayer's own Xofigo (radium-223, EUR 320M 2024, eroding). For a commercial lead, Bayer's thorium platform is now one of several alpha strategies; Actinium-225 plays by BMS/RayzeBio and AstraZeneca/Fusion have stronger targeted-ligand validation, making TTC's competitive position platform-feasibility dependent rather than clinically proven.
Xofigo competes in mCRPC bone-dominant disease where the landscape has shifted dramatically toward PSMA-targeted radioligand therapy. Alpha-emitting radiopharmaceutical (Xofigo's direct MOA): Bayer's Xofigo (radium-223 dichloride) is the only approved alpha-emitter for mCRPC bone metastases with OS benefit (ALSYMPCA), 2024 Bayer sales approximately EUR 320M (declining post-Pluvicto competition). Beta-emitting PSMA radioligand (displacing class): Novartis/Endocyte's Pluvicto (lutetium-177 vipivotide tetraxetan/177Lu-PSMA-617) approved 2022 post-taxane/ARPI, expanded to pre-taxane PSMAfore 2025, 2024 Novartis sales approximately $1.4B — now the dominant mCRPC radioligand. Androgen receptor pathway inhibitors (incumbent SOC): J&J's Erleada (apalutamide) and Zytiga (abiraterone + prednisone, genericized, historically $3B+ peak), Pfizer/Astellas's Xtandi (enzalutamide, approximately $6.0B 2024 combined), Bayer's Nubeqa (darolutamide, EUR 1.3B 2024 and rapidly growing). PARP inhibitors (BRCA/HRR+): AstraZeneca/Merck's Lynparza (olaparib) + abiraterone, Pfizer's Talzenna (talazoparib) + enzalutamide. Taxane chemotherapy: docetaxel, cabazitaxel remain cytotoxic backbone. For a commercial lead, Xofigo's franchise has eroded sharply — Pluvicto's PSMA-targeting, broader metastatic coverage, and newer data have relegated radium-223 to post-Pluvicto or PSMA-negative bone-limited settings.
Bayer completed ~$2.9B acquisition of Algeta ASA, gaining full ownership of Xofigo (radium-223) for metastatic castration-resistant prostate cancer.
ERA 223 trial combining Xofigo with Zytiga halted due to increased fracture and death risk, limiting label expansion opportunities.
Xofigo generated ~$400M peak revenue. Failed ERA 223 expansion trial limited growth. $2.9B price was aggressive for achieved trajectory.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Algeta ASA (this deal) | 2002 | $2.9B | 45 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2002 deals · Bayer AG deals · Oncology deals